ImmunoGen Reports on Investigational B-Cell Compound

This past weekend biotechnology company Immunogen reported on data from an extended Phase I study of their investigational treatment, currently known as SAR3419, at the annual meeting of the American Society of Clinical Oncology.

They said that the investigational compound, for the treatment of non-Hodgkin's lymphoma and other B-cell malignancies showed "improved safety and performance under a modified dosing schedule."

The compound--SAR3419—developed by ImmunoGen and licensed to Sanofi, is one aspect of a much wider company collaboration that involves ImmunoGen's TAP technology, which works like an antibody drug conjugate and delivers a drug payload to specific cells to kill them.

Doing so makes the treatment especially lethal to the cell but not damaging to surrounding tissue, the idea being to reduce side effects and adverse events.

In the Phase I trial, patients that were administered the treatment weekly for four weeks, followed by every two weeks for another four doses showed more improvement than patients dosed weekly.

"We believe the findings reported today support that SAR3419 has the potential to become an important new therapy for key B-cell malignancies," said ImmunoGen President and Chief Executive Daniel Junius said. "These findings also add to the growing body of clinical data supporting that the utility of our TAP technology--and the depth of our product opportunities--extend well beyond any one compound to multiple types of cancers, antibodies, and product designs."

Source: MarketWatch

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...